70 CHF CHF 70.00
AG-CR1-3602-M0055 mgCHF 70.00
AG-CR1-3602-M02525 mgCHF 210.00
|Synonyms||PS-341; LDP-341; MLM-341; MG-341; NSC-681239; Proteasome Inhibitor|
|Purity Chemicals||≥97% (NMR)|
|Solubility||Soluble in DMSO, ethanol or methanol. Slightly soluble in water.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Protect from light.|
|Use/Stability||Stable for at least 1 year after receipt when stored at -20°C.|
|Product Specification Sheet|
- Highly potent, selective and reversible cell permeable inhibitor of the proteasome. Inhibits the chymotrypsin-like and caspase-like peptidase activity of the proteasome.
- Calpain and cathepsin inhibitor.
- Autophagy activator.
- Anticancer compound. Inhibits proliferation and migration of several tumor cell lines with nanomolar potency.
- Apoptosis inducer.
- Proteasome inhibitors: a novel class of potent and effective antitumor agents: J. Adams, et al.; Cancer Res. 59, 2615 (1999)
- Development of the proteasome inhibitor Velcade (Bortezomib): J. Adams & M. Kauffmann; Cancer Invest. 22, 304 (2004)
- Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells: S.T. Nawrocki, et al.; Cancer Res. 65, 11510 (2005)
- A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib: D. Chauhan, et al.; Cancer Cell 8, 407 (2005)
- Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate: A.F. Kisselev, et al.; J. Biol. Chem. 281, 8582 (2006)
- Bortezomib interactions with chemotherapy agents in acute leukemia in vitro: T.M. Horton, et al.; Cancer Chemother. Pharmacol. 58, 13 (2006)
- Bortezomib as an antitumor agent: A.M. Roccaro, et al.; Curr. Pharm. Biotechnol. 7, 441 (2006) (Review)
- Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib: A. Kardosh, et al.; Cancer Res. 68, 843 (2008)
- Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation: C. Li, et al.; J. Biol. Chem. 285, 16096 (2010)
- Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis: M. Hirai, et al.; Blood 117, 500 (2011)
- Bortezomib, a proteasome inhibitor, attenuates angiotensin II-induced hypertension and aortic remodeling in rats: S. Li, et al; PLoS One 8, e78564 (2013)
- Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells: H. Min, et al.; Cancer Chemother. Pharmacol. 74, 167 (2014)
- Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis: A. Ghobadi, et al.; Blood 124, 2752 (2014)
- Bortezomib inhibits C2C12 growth by inducing cell cycle arrest and apoptosis: S.S. Xing, et al.; BBRC 445, 375 (2014)
- Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2: Z. Wang, et al.; Int. J. Oncol. 45, 1469 (2014)
- Efficient apoptosis and necrosis induction by proteasome inhibitor: bortezomib in the DLD-1 human colon cancer cell line: R. Krętowski, et al.; Mol. Cell Biochem. 398, 165 (2015)
- Live cell, image-based high-throughput screen to quantitate p53 stabilization and viability in human papillomavirus positive cancer cells: G. Martinez-Noel, et al.; Virology 560, 96 (2021)